Solution Group Bhd , the Asean manufacturing partner of CanSino Biologics Inc in a statement, said the vaccine was approved for adults aged 18 years and above, regardless of the type of vaccine they received during their earlier Covid-19 vaccination.
The statement also stated that Convidecia will be given as a booster dose after at least three months of recipients receiving the second dose of their primary vaccination. "It is also the first and only Covid-19 vaccine from China to be included in the heterologous vaccination programme in Malaysia that can be administered as a mix-and-match with both Pfizer-BioNTech and AstraZeneca Covid-19 vaccines,” it said Thursday .
In the same statement, SGB’s deputy group managing director Datuk Dr Mohd Nazlee Kamal said recent studies in China showed that usage of Convidecia as a heterologous booster, via either intramuscular injection or using the inhaled version, generated greater neutralising antibody responses. In addition, he said the vaccine's safety profile in real-life usage was also backed by the Mexican health authorities' Events Supposedly Attributable to Vaccination or Immunisation Report released recently. - Bernama
Syed Saddiq Evades A Question: How Would You Steer The Malay Muslim Narrative In That Direction Towards Malaysian Malaysia? Video ringkas:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: staronline - 🏆 4. / 75 Read more »
Source: staronline - 🏆 4. / 75 Read more »